Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study.
Myrtle F KrulNiels F M KokHarun OsmaniFlorian E BuismanBas Groot KoerkampDirk J van GrünhagenCornelis VerhoefBianca MostertPetur SnaebjornssonBram WesterinkElisabeth G KlompenhouwerMaarten L DonswijkTheo J M RuersJoeri A J DoumaNico van BlijderveenT Peter KinghamMichael I D'AngelicaNancy E KemenyKaren BolhuisTineke E BuffartKoert F D KuhlmannPublished in: The British journal of surgery (2024)
HAIP-SYS for borderline resectable and unresectable CRLMs was feasible and safe in the Netherlands. This has led to a successive multicentre phase III randomized trial investigating oncological benefit (EUDRA-CT 2023-506194-35-00). Current trial registration number: clinicaltrials.gov (NCT04552093).
Keyphrases
- liver metastases
- phase ii
- phase iii
- clinical trial
- open label
- locally advanced
- double blind
- rectal cancer
- placebo controlled
- study protocol
- squamous cell carcinoma
- computed tomography
- low dose
- image quality
- radiation therapy
- magnetic resonance
- dual energy
- positron emission tomography
- chemotherapy induced
- prostate cancer
- magnetic resonance imaging